5 Stocks That Hit 52-Week Highs This Week
Discover 5 stocks that hit fresh 52-week highs this week including NVDA, COIN, and RKLB. Get technical analysis, price targets, and Monday trading strategies from our expert team.
TopMomentum
TopMomentum identifying companies with top momentum scores. With a focus on highlighting high-momentum stocks and market trends, TopMomentum provides timely updates and insights to help investors capitalize on strong market performers.
Jun 28 2025
With markets closed this Saturday, it's the perfect time to analyze the standout performers that reached new 52-week highs this week. These momentum stocks are capturing trader attention and could offer significant opportunities when markets reopen Monday.
NVIDIA Corporation
$NVDA continued its relentless run, closing at $157.75 and hitting a fresh high of $158.71 before the market closed for the weekend. Nvidia is riding a wave of bullish momentum as chip stocks rally, supported by AI demand and robust data center growth. Its RSI sits at a strong 76, and with its uptrend firmly intact, traders will be watching to see if NVDA can break higher next week as it hovers near its all-time highs.
Coinbase Global
$COIN hit a 52-week high of $382 earlier this week before pulling back to $353.43, down 5.77% from its peak but maintaining an uptrend with a healthy RSI of 71.43. Coinbase momentum has been supported by renewed crypto interest and ETF exposure through funds like CRPT and FDIG. Traders eyeing crypto’s next leg higher will want to see if COIN can reclaim its high as the new week kicks off.
Abbott Laboratories
$ABT quietly hit a 52-week high of $141.23 this week, closing at $134.36 with a 0.52% gain into the weekend. The healthcare giant has benefited from a broader rally in Indian markets and sector strength in energy, utilities, and metals. With a steady uptrend and a moderate RSI of 51.20, ABT is a stock traders can watch for continued accumulation in a strong healthcare market.
Rocket Lab USA
$RKLB surged 9.37% this week to $35.38, hitting a new high of $37.66. Rocket Lab’s momentum has been fueled by its active launch schedule, with the company completing its third launch this month for HawkEye 360. An RSI of 69.94 and an established uptrend highlight that RKLB remains a momentum play, with traders watching for potential follow-through once markets reopen.
CorMedix Inc
$CRMD spiked to a 52-week high of $17.43 earlier in the week but closed sharply lower at $12.50, down 24.52% on the week. The move came after CorMedix raised its sales guidance, with plans to expand its DefenCath catheter lock solution to more patients. While the RSI remains elevated at 44.10, traders will want to see if CRMD can stabilize and attract buyers after the sharp pullback from its high.
What This Means for Monday's Trading
These stocks hitting 52-week highs represent diverse opportunities across growth sectors. While markets remain closed this weekend, successful traders are already planning their Monday strategies.
The strength in these names suggests underlying market health, but remember that 52-week highs can lead to both breakouts and reversals. Plan accordingly and trade with discipline.
Frequently Asked Questions
Q: Should I buy stocks at 52-week highs?
A: Stocks hitting new highs often have strong momentum, but timing and risk management are crucial. Consider waiting for pullbacks or breakout confirmations.
Q: Which sectors are showing the most strength?
A: Technology (AI/chips), cryptocurrency, healthcare, and aerospace are current leaders based on this week's 52-week high data.
Q: How do I trade stocks that gap up on Monday?
A: Wait for the first 30 minutes to assess volume and direction. Look for either continuation patterns or reversal signals before entering positions.
Latest Analysis
June 27, 2025 02:25 AM
June 26, 2025 10:43 AM
June 26, 2025 06:36 AM
Unlock Exclusive Stock Insights!
Join StocksRunner.com for daily market updates, expert analyses, and actionable insights.
Signup now for FREE and stay ahead of the market curve!
Why Join?
Find out what 10,000+ subscribers already know.
Real-time insights for informed decisions.
Limited slots available, SignUp Now!
Please note that the article should not be considered as investment advice or marketing, and it does not take into account the personal data and requirements of any individual. It is not a substitute for the reader's own judgment, and it should not be considered as advice or recommendation for buying or selling any securities or financial products.
